DCVMN AGM – Inaugural Session

Sai D Prasad
20 Oct 2022
Contents

• DCVMN Overview
• DCVMN Pandemic Response & Industry Feedback
• Ecosystem for Vaccine Industry
• DCVMN Future Direction
• DCVMN Board Activities
• 40+ Innovators and vaccine manufacturers, across 15 countries
• Representing all WHO regions
• More than 50 distinct vaccines, supplied to ~ 170 countries
• ~15 WHO Prequalified vaccine manufacturers
• ~78 prequalified vaccines
DCVM’s PANDEMIC RESPONSE

- 9 manufactures developed innovative vaccines
  - Inactivated vaccines, Ad-vector vaccines, DNA vaccines, Sub-unit vaccines, mRNA vaccines, etc
  - Success in Product development

- ~ Over 11 manufacturers are recipients of technology transfers
  - Ad-vector vaccines, Inactivated vaccines, Sub-unit vaccines, mRNA vaccines etc

- DCVM’s: >50% of global supplies
  - > 8 billion doses
  - Success in Large Scale Manufacturing

- Excellent achievement in technology and Manufacturing,
  - Failure towards equitable access
  - Failure in Financing and Procurement
HEADWINDS FOR INDUSTRY

Pandemic Funding

• > 50% of COVID-19 vaccines supplied by DCVM’s,

Need for reflection: disproportionate allocation vs success rate of deployed funding
• Pandemic Convention / Pandemic Treaty
  • The convention to provide guidance for the free flow of goods, services, knowledge, between countries, During pandemics,
  • To avoid political, financial, trade, knowledge based barriers etc

COVID19 Vaccines

Global Equitable Access

Industry Feedback

• Procurement agencies were more favourable to provide purchase commitments to companies in North America, EU etc,
  • DCVM’s mostly ignored
  • But > 50% manufacturing and supplies from DCVM’s
COVID19 Vaccines

Global Equitable Access

Industry Feedback

• Product development Funding agencies were quick to provide funding support to novel and innovative but unproven technologies,

  • Poor understanding of ......
    • large scale manufacturing capabilities,
    • programmatic suitability,
    • supply and distribution track record,
    • etc,

  • DCVM’s with traditional technologies, and large manufacturing / distribution capabilities were ignored
• Lack of sustainable pricing for an healthy industry
  • Constant downward pressure on vaccines pricing with the intent of making it affordable,
  • Reduction in # of suppliers, market exits by suppliers,
  • Consolidation of existing supplier base with vaccines,
  • Progression towards large volume manufacturers at low cost,

• Access to technology
  • Complex and varied,
  • but accessible,

• Long lead times for vaccinology
  • Vaccine development, regulatory approvals – 10-15 years,
  • Facility development, qualifications, validations, regulatory approvals, - 5-7 years,
  • Investment size ~ > $ 100 million ???
  • Regulatory approvals ~ 2-3 years in each country, post approval in first country,
  • Market access and distribution scale up ~ 5 years post regulatory approvals,
  • ROI ~ 10 years post regulatory approvals,
Ecosystem for Vaccine Industry

1. Human capital
   • Biological sciences, Chemistry, Mathematics, Statistics, pharmaceutics, etc
   • Engineering, chemical, mechanical, electrical, electronics, computer sciences, etc
   • Medicine, veterinary sciences, epidemiology, etc

2. Academic research environment

3. Vendors and suppliers: network / ecosystem

4. Financing: readily available
   • Long term low cost debt,
   • private equity,

5. Global Logistics and distribution access

6. **Stable political environment**

7. **Strong regulatory system**

8. **Sustainable pricing for an healthy industry**
DCVMN Activities

- Vaccines / Vaccinations – Advocacy
- Learning Agenda
  - Webinars, Workshops, Vaccinology courses,
- Regulatory Systems Harmonization
  - CRP, testing, audits, clinical trials, etc
- Healthy and Sustainable Industry
  - Value based pricing
  - Innovation driven product development
  - Partnerships
Input: Working Groups

- Supply Chain
- Regulatory Affairs
- Pharmacovigilance
- 3Rs / PSPT
- COVID Committee
- Clinical & Medical affairs

Output: Internal / External Communications

- Position Papers
- Publications
- Stakeholder Communication
DCVMN

Annual General Meeting 2022

Thank You

- 433 Attendees
- 41 Member companies
- 29 Attending in Person
- 37 Countries
- 38 Guest Organizations / Companies / Sponsors